Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence

Purpose: The aim of this study was to evaluate the safety, efficacy, and morphological response of intravitreal ranibizumab biosimilar (Razumab) in neovascular age-related macular degeneration (n-AMD) up to 12 weeks. Methods: Retrospective analysis of 20 eyes of n-AMD receiving 4 weekly intravitreal...

Full description

Bibliographic Details
Main Authors:	Aditya S Kelkar, Jai Kelkar, Mounika Bolisetty, Shreekant B Kelkar
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2021-01-01
Series:	Indian Journal of Ophthalmology
Subjects:	age-related macular degeneration anti-vegf biosimilars optical coherence tomography razumab
Online Access:	http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=6;spage=1469;epage=1474;aulast=Kelkar

Similar Items

Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
by: Shashikant Sharma, et al.
Published: (2021-03-01)

A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion
by: Shashikant Sharma, et al.
Published: (2020-07-01)

Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
by: Lalit Verma, et al.
Published: (2021-01-01)

Clinical effectiveness and safety of razumab (a biosimilar of ranibizumab)
by: Sriram Gopal, et al.
Published: (2020-01-01)

Biosimilars in ophthalmology: “Is there a big change on the horizon?”
by: Sharma A, et al.
Published: (2018-10-01)

Pipeline therapies for neovascular age related macular degeneration
by: Sruthi Arepalli, et al.
Published: (2021-10-01)

Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
by: Jay U Sheth, et al.
Published: (2021-01-01)

Safety and efficacy of Razumab – The new biosimilar in India: Our experience
by: V V Sameera, et al.
Published: (2016-01-01)

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
by: Kabanarou SA, et al.
Published: (2017-05-01)

Asymmetric response to ranibizumab in mixed choroidal neovascularization in a neovascular age-related macular degeneration diagnosed on OCT angiography – case report
by: Martin Pencak, et al.
Published: (2021-01-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
by: Flora Elwes, et al.
Published: (2018-01-01)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
by: Pongsachareonnont P, et al.
Published: (2018-09-01)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
by: Apsangikar P, et al.
Published: (2021-07-01)

Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab
by: Lucia Gonzalez-Buendia, et al.
Published: (2017-08-01)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
by: Christof Haensli, et al.
Published: (2021-06-01)

The burden of neovascular age-related macular degeneration: a patient’s perspective
by: Spooner KL, et al.
Published: (2018-12-01)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
by: Fong AH, et al.
Published: (2013-04-01)

Factors affecting the efficacy of treatment and recurrence in intravitreal ranibizumab applications in neovascular age-related macular degeneration
by: Özlem Kuru, et al.
Published: (2015-06-01)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
by: Dervenis N, et al.
Published: (2016-06-01)

Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
by: Pelin Kıyat, et al.
Published: (2021-06-01)

Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy
by: Arunbalaji Pugazhendhi, et al.
Published: (2021-01-01)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
by: Mohamed A. Hamid, et al.
Published: (2021-04-01)

Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
by: Mohamed Kamel Soliman, et al.
Published: (2021-09-01)

Long-term outcomes of Ranibizumab treatment in neovascular age-related macular degeneration
by: Burak Simsek, et al.
Published: (2018-02-01)

Comparison of efficacy between Ranibizumab and Conbercept for wet age-related macular degeneration
by: Qiang Fan, et al.
Published: (2018-08-01)

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
by: Francisco Jose Rodriguez, et al.
Published: (2019-01-01)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
by: Spooner K, et al.
Published: (2017-01-01)

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
by: Zhe-Li Liu, et al.
Published: (2013-04-01)

LRG1 Expression Is Elevated in the Eyes of Patients with Neovascular Age-Related Macular Degeneration
by: Lucia Mundo, et al.
Published: (2021-08-01)

Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy
by: So Young Han, et al.
Published: (2015-02-01)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
by: Sam Razavi, et al.
Published: (2021-02-01)

Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
by: Jose Navarro-Partida, et al.
Published: (2021-09-01)

Optical coherence tomography findings in macular hole complicating exudative age-related macular degeneration treated with ranibizumab
by: Rosa Dolz-Marco
Published: (2013-08-01)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
by: Suzuki H, et al.
Published: (2017-08-01)

Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
by: Phan LT, et al.
Published: (2021-08-01)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021-09-01)

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
by: Wang LP, et al.
Published: (2018-10-01)

Spontaneous Closure of a Full-Thickness Stage 2 Idiopathic Macular Hole without Posterior Vitreous Detachment
by: Aditya Shreekant Kelkar, et al.
Published: (2013-10-01)